evidence: However, COVID-19-induced healthcare service reconfiguration and recovery have, to date, not been informed by the near real-time hospital data quantifying the extent of disruption for patients with cancer resulting from this service reconfiguration, nor its impact on excess deaths in people with cancer. A previous study has employed literature-based estimates to model the impact of potential diagnostic delays in colorectal cancer during the COVID-19 pandemic.14 15 Short-term (30 days) death in people with cancer and COVID-19 is importantly driven by (treatable) comorbidities such as hypertension and cardiovascular disease.16 Public Health England (PHE) has identified patients with these and a wide range of other non-malignant conditions at greater risk of developing severe illness from SARS-CoV-2 exposure,17 18 while multimorbidity in cancer is an increasing clinical concern.19 20 For general practitioners and oncologists, evidence is required on the pan-cancer estimation of mortality risks according to type and number of comorbid conditions. Such evidence may inform individual decisions about physical isolation and shielding, as well as the need to ensure that patients access specialist cancer care and seek preventive care for non-malignant comorbidities.